Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,560.18
(
-0.70%
)
US TECH 100
23,468.40
(
-1.06%
)
Dow Jones
45,823.96
(
-0.43%
)
Brent Oil
106.22
(
1.71%
)
Bitcoin
69,974.00
(
0.11%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 152025

Monday, 11/12/2012 12:38:12 PM

Monday, November 12, 2012 12:38:12 PM

Post# of 257262
ACHN (-11%) evidently did not impress investors with the HCV update and CC this morning from AASLD:

http://finance.yahoo.com/news/achillion-provides-clinical-hcv-development-115647492.html

ACHN presented little new info—mainly phase-1b monotherapy data for ACH-2684 in cirrhotic patients.

In this fiercely competitive landscape, slow, steady progress is tantamount to losing ground, so the selloff in ACHN’s shares today may be justified.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today